Cargando…

The Effects of the Factors Related to the Patient and the Disease on the Performance of Ablation Therapy in Patients with Differentiated Thyroid Cancer who have Received I-131 Ablation Therapy

Objective: To investigate whether the factors related to the patient and the disease have any effect on the success of ablation therapy in patients with differentiated thyroid cancer who have received I-131 ablation therapy. Material and Methods: All the patients with differentiated thyroid cancer w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Şengöz, Tarık, Sürücü, Erdem, Demir, Yusuf, Derebek, Erkan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590978/ https://www.ncbi.nlm.nih.gov/pubmed/23487510 http://dx.doi.org/10.4274/Mirt.25744

Ejemplares similares

Impact of thyroiditis on (131)I uptake during ablative therapy for differentiated thyroid cancer
por: Lim, Eugenie S, et al.
Publicado: (2019)

Radiation Safety and External Radiation Exposure Rate of Patients Receiving I-131 Therapy for Hyperthyroidism and Remnant Ablation as Outpatient: An Institutional Experience
por: Bhatia, Nisha, et al.
Publicado: (2023)

The Value of Pre-Ablative I-131 Scan for Clinical Management in Patients With Differentiated Thyroid Carcinoma
por: van der Boom, Trynke, et al.
Publicado: (2021)

Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer
por: Iwano, Shingo, et al.
Publicado: (2020)

Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy
por: Janszen, Erica W.M., et al.
Publicado: (2008)

The use of pre-test and post-test probability values as criteria before selecting patients to undergo coronary angiography in patients who have ischemic findings on myocardial perfusion scintigraphy
por: Şen, Nazlı Pınar Karahan, et al.
Publicado: (2016)

An indirect high iodine ((131)I) effective dose used for thyroid ablation in patients with thyroid cancer. Is the method of measurement important?
por: Al‐Shakhrah, Issa A.
Publicado: (2020)

I-131 remnant ablation after thyroidectomy induced hepatotoxicity in a case of thyroid cancer
por: Lin, Rong, et al.
Publicado: (2015)

Efficacy and Affecting Factors of (131)I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
por: Wang, Chen, et al.
Publicado: (2018)

Choice in Ablative Therapies for Thyroid Nodules
por: Hu, Q Lina, et al.
Publicado: (2023)

The Effect of Radioiodine on the Intima Media Thickness of the Carotid Artery
por: Sürücü, Erdem, et al.
Publicado: (2013)

Prevalence of Hyponatremia in Hypothyroid Patients during Radioactive (131)I Ablation for Differentiated Thyroid Cancer: Single Institution Experience
por: Dayrit, Juan Carlo P., et al.
Publicado: (2016)

Unexpected Uptake by the Gallbladder in Post-Ablative I-131 Scan
por: Ünal, Kemal, et al.
Publicado: (2015)

Normal Gallbladder Visualization during Post-Ablative Iodine-131 Scan of Thyroid Cancer
por: Seok, Ju-Won, et al.
Publicado: (2005)

Is (131)I ablation necessary for patients with low-risk papillary thyroid carcinoma and slightly elevated stimulated thyroglobulin after thyroidectomy?
por: Rosario, Pedro Weslley, et al.
Publicado: (2016)

TSH ≥30 mU/L may not be necessary for successful (131)I remnant ablation in patients with differentiated thyroid cancer
por: Ju, Nianting, et al.
Publicado: (2023)

The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma
por: Zhang, Haiying, et al.
Publicado: (2014)

Erratum to: Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience
por: AL-Qahtani, Khalid Hussain, et al.
Publicado: (2016)

Nonsurgical Management of Thyroid Nodules: The Role of Ablative Therapies
por: Stan, Marius N, et al.
Publicado: (2021)

Baker’s Cyst on F-18 FDG PET/CT in a Patient with Ocular Melanoma
por: Cayvarlı, Hakan, et al.
Publicado: (2012)

Unfavorable efficacy to (131)I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb
por: Zhang, Na, et al.
Publicado: (2017)

I-131 for Remnant Ablation in Differentiated Thyroid Cancer After Thyroidectomy: A Meta-Analysis of Randomized Controlled Evidence
por: Shengguang, Yan, et al.
Publicado: (2016)

Endoscopic ablation is a cost-effective cancer preventative therapy in patients with Barrett’s esophagus who have elevated genomic instability
por: Das, Ananya, et al.
Publicado: (2016)

Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with (131)I in Hypothyroidism or with Recombinant Human Thyroid-Stimulating Hormone for Remnant Ablation
por: Signore, Alberto, et al.
Publicado: (2022)

A practical individualized radiation precaution based on the dose rate at release time after inpatient (131)I ablation therapy
por: Han, Sangwon, et al.
Publicado: (2021)

Effect of (131)I Therapy on Complete Blood Count in Patients with Differentiated Thyroid Cancer
por: Rui, Zhongying, et al.
Publicado: (2021)

Gut microbiota is associated with response to (131)I therapy in patients with papillary thyroid carcinoma
por: Zheng, Lei, et al.
Publicado: (2022)

Preablation Stimulated Thyroglobulin/TSH Ratio as a Predictor of Successful I(131)Remnant Ablation in Patients with Differentiated Thyroid Cancer following Total Thyroidectomy
por: Zubair Hussain, Syed, et al.
Publicado: (2014)

Ectopic Pelvic Kidney Mimicking Sacral Metastasis on Post-Therapy Iodine-131 Scan of a Thyroid Cancer Patient
por: Soyluoğlu Demir, Selin, et al.
Publicado: (2017)

I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy
por: Probst, Stephan, et al.
Publicado: (2018)

Thyroid hormone replacement one day before (131)I therapy in patients with well-differentiated thyroid cancer
por: Kayano, Daiki, et al.
Publicado: (2013)

Dosimetry during adjuvant (131)I therapy in patients with differentiated thyroid cancer-clinical implications
por: Szumowski, Piotr, et al.
Publicado: (2021)

Normalization of lymphocyte count after high ablative dose of I-131 in a patient with chronic lymphoid leukemia and secondary papillary carcinoma of the thyroid. Case report
por: Thom, Anneliese Rosmarie Gertrud Fischer, et al.
Publicado: (2014)

A case of the accumulation of 131-iodine in the mammary gland after remnant ablation for papillary thyroid carcinoma on lactating period
por: Murayama, Daisuke, et al.
Publicado: (2021)

Urinary Exosomal Thyroglobulin in Thyroid Cancer Patients With Post-ablative Therapy: A New Biomarker in Thyroid Cancer
por: Huang, Tse-Ying, et al.
Publicado: (2020)

Clinical and functional results of radiofrequency ablation and microwave ablation in patients with benign thyroid nodules
por: Javadov, Mirkhalig, et al.
Publicado: (2021)

Gallbladder Visualization on I-131 Post-Ablative Whole Body Imaging Mimicking Hepatic Metastases
por: Welte, Frank J., et al.
Publicado: (2015)

Deep learning enables automated localization of the metastatic lymph node for thyroid cancer on (131)I post-ablation whole-body planar scans
por: Kavitha, MuthuSubash, et al.
Publicado: (2020)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017)

Recombinant TSH Stimulated Remnant Ablation Therapy in Thyroid Cancer: The Success Rate Depends on the Definition of Ablation Success—An Observational Study
por: van der Horst-Schrivers, Anouk N. A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tr5t44fpe7ek20he2r23c1063r